Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05047536 · OUTCOME

Overall Survival of Participants Treated With KZR-261

KZR-261 in Subjects With Advanced Solid Malignancies · Source last updated 2025-12-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
weeks
Interval / dispersion
95% Confidence Interval
Time frame
20 months

What was measured

Time of overall survival for participants treated with KZR-261.

Analysis population: The Response Evaluable Population is defined as all participants who received at least 1 dose of study treatment (KZR-261) and who have a baseline and at least 1 post-baseline anti-tumor response assessment.

Groups in this outcome

Dose 1

Participants received 1.8 mg/m\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.

Dose 2

Participants received 3.6 mg/m\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.

Dose 3

Participants received 7.2 mg/m\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.

Dose 4

Participants received 12 mg/m\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.

Dose 5

Participants received 18 mg/m\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.

Dose 6

Participants received 27 mg/m\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.

Dose 7

Participants received 40 mg/m\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.

Dose 8

Participants received 60 mg/m\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.

Dose 9

Participants received 80 mg/m\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.

Melanoma Expansion Cohort

Participants received 60 mg/m\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dose 12
Dose 22
Dose 31
Dose 45
Dose 51
Dose 62
Dose 72
Dose 810
Dose 92
Melanoma Expansion Cohort4

Reported measurements

Source class 1
Values in weeks · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Dose 121.7Not reported21.0NANA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.
Dose 222.6Not reported12.6NANA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.
Dose 3NANot reported15.0NANA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.
Dose 417.9Not reported8.4NANA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.
Dose 5NANot reported39.7NANA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.
Dose 6NANot reported33.9NANA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.
Dose 753.4Not reported11.7NANA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.
Dose 812.4Not reported7.926.1Not reported
Dose 9NANot reported9.3NANA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.
Melanoma Expansion Cohort24.6Not reported19.4NANA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        NA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.
        group Id
        OG000
        lower Limit
        21.0
        upper Limit
        NA
        value
        21.7
      2. comment
        NA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.
        group Id
        OG001
        lower Limit
        12.6
        upper Limit
        NA
        value
        22.6
      3. comment
        NA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.
        group Id
        OG002
        lower Limit
        15.0
        upper Limit
        NA
        value
        NA
      4. comment
        NA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.
        group Id
        OG003
        lower Limit
        8.4
        upper Limit
        NA
        value
        17.9
      5. comment
        NA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.
        group Id
        OG004
        lower Limit
        39.7
        upper Limit
        NA
        value
        NA
      6. comment
        NA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.
        group Id
        OG005
        lower Limit
        33.9
        upper Limit
        NA
        value
        NA
      7. comment
        NA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.
        group Id
        OG006
        lower Limit
        11.7
        upper Limit
        NA
        value
        53.4
      8. group Id
        OG007
        lower Limit
        7.9
        upper Limit
        26.1
        value
        12.4
      9. comment
        NA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.
        group Id
        OG008
        lower Limit
        9.3
        upper Limit
        NA
        value
        NA
      10. comment
        NA = Not calculable because the event of interest did not occur in a sufficient number of participants to allow estimation.
        group Id
        OG009
        lower Limit
        19.4
        upper Limit
        NA
        value
        24.6
denoms
  1. counts
    1. group Id
      OG000
      value
      2
    2. group Id
      OG001
      value
      2
    3. group Id
      OG002
      value
      1
    4. group Id
      OG003
      value
      5
    5. group Id
      OG004
      value
      1
    6. group Id
      OG005
      value
      2
    7. group Id
      OG006
      value
      2
    8. group Id
      OG007
      value
      10
    9. group Id
      OG008
      value
      2
    10. group Id
      OG009
      value
      4
    units
    Participants
description
Time of overall survival for participants treated with KZR-261.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants received 1.8 mg/m\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.
    id
    OG000
    title
    Dose 1
  2. description
    Participants received 3.6 mg/m\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.
    id
    OG001
    title
    Dose 2
  3. description
    Participants received 7.2 mg/m\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.
    id
    OG002
    title
    Dose 3
  4. description
    Participants received 12 mg/m\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.
    id
    OG003
    title
    Dose 4
  5. description
    Participants received 18 mg/m\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.
    id
    OG004
    title
    Dose 5
  6. description
    Participants received 27 mg/m\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.
    id
    OG005
    title
    Dose 6
  7. description
    Participants received 40 mg/m\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.
    id
    OG006
    title
    Dose 7
  8. description
    Participants received 60 mg/m\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.
    id
    OG007
    title
    Dose 8
  9. description
    Participants received 80 mg/m\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.
    id
    OG008
    title
    Dose 9
  10. description
    Participants received 60 mg/m\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.
    id
    OG009
    title
    Melanoma Expansion Cohort
param Type
MEDIAN
population Description
The Response Evaluable Population is defined as all participants who received at least 1 dose of study treatment (KZR-261) and who have a baseline and at least 1 post-baseline anti-tumor response assessment.
reporting Status
POSTED
time Frame
20 months
title
Overall Survival of Participants Treated With KZR-261
type
SECONDARY
unit Of Measure
weeks

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice